Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Its pipeline includes AP-PA02, an inhaled phage targeting Pseudomonas aeruginosa in cystic fibrosis, and AP-SA02, targeting Staphylococcus aureus. The company has completed three Phase 2 randomized, double-blind, placebo-controlled clinical trials and operates a cGMP-compliant bacteriophage manufacturing facility in Los Angeles.
expected 2026-12-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001104659-26-034532 | EDGAR | 78K words |
| 2025-03-21 | 2024-12-31 | 0001558370-25-003406 | EDGAR | 70K words |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003706 | EDGAR | 68K words |
| 2023-03-16 | 2022-12-31 | 0001558370-23-004014 | EDGAR | 87K words |
| 2022-03-17 | 2021-12-31 | 0001558370-22-003845 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001558370-21-003202 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001558370-20-002943 | EDGAR | — |
| 2019-03-25 | 2018-12-31 | 0001144204-19-015711 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001144204-18-014652 | EDGAR | — |
| 2017-03-27 | 2016-12-31 | 0001144204-17-016833 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001104659-26-094907 | EDGAR | 27K words |
| 2025-11-12 | 2025-09-30 | 0001104659-25-110383 | EDGAR | 24K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011235 | EDGAR | 23K words |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007765 | EDGAR | 21K words |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015530 | EDGAR | 22K words |
| 2024-08-13 | 2024-06-30 | 0001558370-24-012061 | EDGAR | 21K words |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007068 | EDGAR | 18K words |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019036 | EDGAR | 22K words |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014701 | EDGAR | 19K words |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009372 | EDGAR | 35K words |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017141 | EDGAR | 34K words |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013269 | EDGAR | 33K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-23 | 0001104659-26-109809 | EDGAR | 1K words |
| 2026-09-14 | 0001104659-26-107253 | EDGAR | 1K words |
| 2026-08-12 | 0001104659-26-094896 | EDGAR | 3K words |
| 2026-07-20 | 0001104659-26-084861 | EDGAR | 1K words |
| 2026-07-20 | 0001104659-26-084860 | EDGAR | 3K words |
| 2026-07-13 | 0001104659-26-082850 | EDGAR | 1K words |
| 2026-04-02 | 0001104659-26-039180 | EDGAR | 1K words |
| 2026-03-25 | 0001104659-26-034523 | EDGAR | 2K words |
| 2026-03-19 | 0001104659-26-031715 | EDGAR | 2K words |
| 2026-02-23 | 0001104659-26-018333 | EDGAR | 1K words |
452 total filings indexed. 420 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000921114 |
| Ticker | ARMP |
| Exchange | NYSE |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | WA |
| Headquarters | Los Angeles, California |
| Website | https://www.armatapharma.com |
| Listed | 1994-05-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ARMP (~200 tokens, structured JSON with cryptographic provenance)